- Founder(s): Prof. Thomas Thum, Dr. Sandor Batkai and Dr. Claudia Ulbrich
- Established: June 2016
- CEO(s): Dr. Claudia Ulbrich
- Employees: 10
- Financial Data: Privately funded
- Website: cardior.de
Cardior is developing a proprietary RNA technology to revolutionize heart failure treatment. This company aims to be the international leader in noncoding RNA-based therapies for cardiovascular diseases.
The molecular target is a noncoding RNA, that simultaneously controls cardiac growth, autophagy and calcium handling as well as contractility of cardiomyocytes. Thus its inhibition reverses maladaptive cardiac remodeling and restores normal cardiac function.
Cardior estimates its market potential to exceed up to €2 billion in peak sales for Germany, France, Italy, Spain, the United Kingdom (a.k.a. the “EU Top 5”) and the United States.
In regards to its location, the company is embedded into a strong network of academic and industrial partners. This includes the Hannover Medical School (MHH), the Fraunhofer Institute (ITEM), the Clinical Research Center (CRC) Hannover and the Institute of Prof. Thum (Institute of Molecular and Translational Therapeutic Strategies – IMTTS).